The addition of bevacizumab to chemotherapy beyond disease progression may be effective in patients with advanced non-small cell lung cancer (NSCLC) whose disease has progressed after treatment with bevacizumab plus a platinum-based doublet, a study published online ahead of print in the journal Cancer has shown.1

Although bevacizumab plus platinum-based chemotherapy is an established standard treatment option for the treatment of advanced nonsquamous NSCLC in the first-line setting, there has been limited evidence to support the use of bevacizumab beyond disease progression.

For the multicenter, open-label, phase 2 trial, researchers enrolled 100 patients with recurrent or metastatic nonsquamous NSCLC who experienced disease progression after frontline therapy with bevacizumab plus a platinum-based doublet. Participants were randomly assigned 1:1 to receive docetaxel with or without bevacizumab.

Results showed that median progression-free survival was 3.4 months with docetaxel alone compared with 4.4 months with docetaxel and bevacizumab (HR, 0.71; P=.058), which was considered statistically significant.

Researchers found that median overall survival was 11.0 months (95% CI: 7.6-16.1) and 13.1 months (95% CI: 10.6-21.4) with docetaxel alone and docetaxel plus bevacizumab, respectively (HR, 0.74; 95% CI: 0.46-1.19; P=.11).

In terms of safety, no unexpected or severe adverse events were reported in either arm.

The findings suggest that further evaluation of bevacizumab beyond disease progression in this patient population is warranted.

REFERENCE

1. Takeda M, Yamanaka T, Seto T, et al. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial [published online ahead of print February 1, 2016]. Cancer. doi:10.1002/cncr.29893.